[Diagnosis and management of essential tremor].

Essential tremor (ET) is the most common extrapyramidal disease and one of the most frequent neurological diseases. The main presentation of ET is a progressive bilateral (kinetic-postural) hand tremor. The prevalence in people over 65 years is 5%, it increases with age up to 22% in people over 95 years.

[Diagnosis and effective surgical treatment of constrictive pericarditis].

Constrictive pericarditis is a rare and severe disease. Timely and correct differential diagnosis of this pathology facilitates choice of necessary tactics of treatment and thus improve prognosis and quality of life. In this paper we present clinical case report of a patient with constrictive pericarditis.

[Clinical value of antracycline toxicity: modern approaches to diagnosis, prevention, and treatment].

In this literature review we present analysis of various aspects of the problem of cardiotoxicity of antracyclines used for the treatment of the breast cancer. We consider mechanisms of their cardiotoxic action, role of risk factors, clinical manifestations of acute and chronic cardiotoxicity, and dependence of their severity on treatment duration and drug dose. We give data on contemporary methods of diagnostics of early toxic cardiac effects of antracyclines from the side of cardiovascular system.

[Dysport in the treatment of essential tremor].

Head tremor develops in one-third of patients with essential tremor. It is resistant to peroral antitremor medications. The efficacy of dysport, a botulinum toxin type A preparation, injected in the neck muscles, was examined in 12 patients with head tremor.

[Long term use of a non-selective beta-blocker with vasodilating properties carvedilol in patients with severe heart failure].

Results of drug treatment of 51 patients (41 men, 10 women) aged 35-86 years (mean age 62 years) included into COPERNICUS trial are presented. All patients had compensated NYHA class IV chronic heart failure and left ventricular ejection fraction less than 25%. For at least 2 months the patients received therapy with diuretics and angiotensin converting enzyme inhibitors (84%) or angiotensin receptor blockers (16%) and then were randomized to either carvedilol or placebo.